Yamamoto S - Search Results

1

Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation.

Yamamoto K, Yamamoto S, Kato K. Yamamoto K, et al. Among authors: yamamoto s. Expert Opin Drug Saf. 2024 Jun;23(6):667-675. doi: 10.1080/14740338.2024.2348554. Epub 2024 May 1. Expert Opin Drug Saf. 2024. PMID: 38676380 Review.

2

Oral chemotherapy for the treatment of hepatocellular carcinoma.

Yamamoto S, Kondo S. Yamamoto S, et al. Expert Opin Pharmacother. 2018 Jun;19(9):993-1001. doi: 10.1080/14656566.2018.1479398. Epub 2018 Jun 18. Expert Opin Pharmacother. 2018. PMID: 29913090 Review.

3

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.

Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Masuda K, et al. Among authors: yamamoto s. BMC Cancer. 2019 Oct 21;19(1):974. doi: 10.1186/s12885-019-6150-y. BMC Cancer. 2019. PMID: 31638948 Free PMC article.

4

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.

Kawai S, Fukuda N, Yamamoto S, Mitani S, Omae K, Wakatsuki T, Kato K, Kadowaki S, Takahari D, Boku N, Muro K, Machida N. Kawai S, et al. Among authors: yamamoto s. BMC Cancer. 2020 Apr 21;20(1):338. doi: 10.1186/s12885-020-06865-7. BMC Cancer. 2020. PMID: 32316940 Free PMC article.

5

Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).

Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Nagashima K, Aoki K, Mizoguchi Y, Kitano S, Yachida S, Shiba S, Kitagawa Y. Yamamoto S, et al. Future Oncol. 2020 Jul;16(19):1351-1357. doi: 10.2217/fon-2020-0189. Epub 2020 May 12. Future Oncol. 2020. PMID: 32396014

6

Pembrolizumab for the treatment of esophageal cancer.

Yamamoto S, Kato K. Yamamoto S, et al. Expert Opin Biol Ther. 2020 Oct;20(10):1143-1150. doi: 10.1080/14712598.2020.1792881. Epub 2020 Jul 14. Expert Opin Biol Ther. 2020. PMID: 32620063 Review.

7

Immuno-oncology for esophageal cancer.

Yamamoto S, Kato K. Yamamoto S, et al. Future Oncol. 2020 Nov;16(32):2673-2681. doi: 10.2217/fon-2020-0545. Epub 2020 Aug 11. Future Oncol. 2020. PMID: 32777942 Free article.

8

Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma.

Takamizawa S, Honma Y, Murakami N, Mori T, Oka H, Yamamoto S, Kashihara T, Ito K, Kubo Y, Ikeda A, Matsumoto F, Omura G, Kobayashi K, Itami J, Kato K, Yoshimoto S. Takamizawa S, et al. Among authors: yamamoto s. Invest New Drugs. 2021 Apr;39(2):564-570. doi: 10.1007/s10637-020-00999-y. Epub 2020 Sep 17. Invest New Drugs. 2021. PMID: 32940872

9

Nivolumab for the treatment of esophageal cancer.

Mikuni H, Yamamoto S, Kato K. Mikuni H, et al. Among authors: yamamoto s. Expert Opin Biol Ther. 2021 Jun;21(6):697-703. doi: 10.1080/14712598.2021.1904887. Epub 2021 Mar 29. Expert Opin Biol Ther. 2021. PMID: 33736560

10

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer.

Takamizawa S, Shoji H, Hirano H, Izutsu K, Yamamoto S, Iwasa S, Honma Y, Okita N, Takashima A, Kato K, Boku N. Takamizawa S, et al. Among authors: yamamoto s. Case Rep Oncol. 2021 Feb 25;14(1):85-89. doi: 10.1159/000512821. eCollection 2021 Jan-Apr. Case Rep Oncol. 2021. PMID: 33776687 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10,343 results

Search Page